SIDEBAR: FDA-Approved Drugs to Use as Single Agents or in Combination Chemotherapy

Get Permission


Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic NSCLC with disease progression on or who are intolerant to crizotinib; mercaptopurine as a 20 mg/mL oral suspension for the treatment of acute lymphoblastic leukemia as part of a combination regimen; siltuximab for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus-negative and human herpesvirus-8-negative; ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate; ramucirumab as a single agent in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma; ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukemia (ibrutinib was approved in 2013 for the treatment of mantle cell lymphoma); trametinib and dabrafenib for use in combination in the treatment of unresectable or metastatic BRAF V600E or V600K mutation metastatic melanoma.


Crizotinib for ALK-positive advanced non-small cell lung cancer; ­ibrutinib and lenalidomide in the treatment of mantle cell lymphoma; obinutuzumab for use in combination with chlorambucil in the treatment of chronic lymphocytic leukemia; pertuzumab injection for use in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive breast cancer; paclitaxel in combination with gemcitabine for first-line treatment of advanced adenocarcinoma of the pancreas; afatinib and erlotinib for the first-line treatment of EGFR exon 19 deletions or exon 21 substitution mutations metastatic non–small cell lung cancer; trametinib for BRAF V600E or V600K mutation advanced melanoma; ­dabrafenib for BRAF 600E mutation metastatic melanoma; ado-trastuzumab ­emtansine as a single agent in HER-2 positive advanced breast cancer patients who received prior therapy with trastuzumab and a taxane; doxorubicin hydrochloride liposome injection for advanced ovarian cancer and for AIDS-related Kaposi’s sarcoma; bevacizumab for use in combination with fluoropyrimide-irinotecan or fluoropyrimidine-oxaliplatin-based chemotherapy for metastatic colorectal cancer.

Related Articles

One Community

My Presidential theme was One Community. I think that theme continues to express much of our goal in oncology, which is to make sure that all members of the cancer care team work together—oncologists, nurses, scientists, nutritionists, psychologists, social workers, administrators, and others.





By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.